ST20-P2T: Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand

• Sponsor: Boston University (Other)
• Overall Status: Completed
• CT.gov ID: NCT01609595
• Collaborator: Mahidol University (Other)
• Enrollment: 10
• Location: 1
• Arm: 1
• Duration (Months): 9
• Patients Per Site Per Month: 1.1

Study Details

Study Description

Brief Summary

Beta thalassemia intermedia is an inherited blood disease caused by molecular mutations which reduce the beta globin protein chain of adult hemoglobin A, the protein in red blood cells which carries oxygen throughout the body. Beta thalassemias cause progressively severe anemia, widespread organ damage, and often require blood transfusions. There is no FDA approved therapeutic to treat the underlying cause of beta thalassemia. Fetal hemoglobin is another type of endogenous hemoglobin which can replace the reduced beta globin protein, reduce the anemia, and even abolish transfusion requirements. This type of hemoglobin is normally suppressed in infancy.

Sodium 2,2 dimethylbutyrate (ST20, or HQK-1001) is a small molecule which stimulates production of fetal hemoglobin in nonhuman primates and in human patients in Phase I/II trials.

This is a Phase 2 open-label trial to evaluate the ability of this oral therapeutic to reduce anemia in patients with beta thalassemia intermedia, when administered once daily for 26 weeks. All participants will receive the study drug.

Condition or Disease	Intervention/Treatment	Phase
Beta Thalassemia Intermedia	Drug: sodium 2,2 dimethylbutyrate	Phase 2

Detailed Description

This trial will:

1. Determine the proportion of patients in which treatment with the study drug results in an increase in total hemoglobin by 1.5 g/dl above baseline levels when administered for 26 weeks in Thai patients with beta thalassemia intermedia, including Hemoglobin E beta thalassemia.

2. Determine the number and proportion of participants in whom treatment with the study drug results in an increase in fetal hemoglobin.

3. Determine the number of participants who have adverse events.

Study Design

• Study Type: Interventional
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label Academic Phase 2 Study of SDMB in Subjects in Thailand With Beta Thalassemia Intermedia
• Study Start Date: Mar 1, 2012
• Actual Primary Completion Date: Nov 1, 2012
• Actual Study Completion Date: Dec 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment Study drug treatment	Drug: sodium 2,2 dimethylbutyrate; Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks; Other Names: HQK-1001, ST20

Outcome Measures

Primary Outcome Measures

1. The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment. [Within 30 weeks, including 26 weeks of dosing with the study drug]

   Baseline hemoglobin levels will be determined by averaging 2 values prior to administration of the study drug. The number of participants in which an increase in total hemoglobin of at least 1.5 g/dL above baseline occurs will be determined.

Secondary Outcome Measures

1. The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels. [Within 30 weeks, including 26 weeks of study drug administration]

   Tests of fetal hemoglobin will be obtained at two times prior to administration of the study drug and will be averaged. Laboratory tests of fetal hemoglobin will be assessed monthly during the study drug administration for 26 weeks, as a biomarker of drug activity.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosis of Beta Thalassemia Intermedia

• Splenectomized

• Average of two Hgb levels between 6.0 and 9.0 g/dl

Exclusion Criteria:

• Red blood cell transfusion within 3 months of study drug initiation

• Enlarged spleen

• Use of hydroxyurea within 6 months

• QT Segment corrected (QTc)> 450 msec (men) or 470 msec (women) on screening ECG

• Use of iron chelating agents within 7 days of first dose

• Alanine Transaminase(ALT)> 4 times the upper limit of normal

• Use of erythropoiesis stimulating agents (ESAs) within 90 days of first dose

• serum creatinine > 1.5 mg/dL

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mahidol University Thalassemia Research Centre	Nakhonpathom		Thailand

Sponsors and Collaborators

• Boston University
• Mahidol University

Investigators

• Principal Investigator: Suthat Fuchareon, MD, Thalassemia Research Centre, Mahidol University

Study Documents (Full-Text)

None provided.

More Information

Publications

• Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S. Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci. 2010 Aug;1202:158-64. doi: 10.1111/j.1749-6632.2010.05593.x.
• Perrine SP, Wargin WA, Boosalis MS, Wallis WJ, Case S, Keefer JR, Faller DV, Welch WC, Berenson RJ. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol. 2011 Aug;51(8):1186-94. doi: 10.1177/0091270010379810. Epub 2011 Mar 21.

• Responsible Party: Susan P. Perrine, Sponsor Investigator, Boston University
• ClinicalTrials.gov Identifier: NCT01609595
• Other Study ID Numbers: ST20-P2T; HQK-1001-Thal P2
• First Posted: Jun 1, 2012
• Last Update Posted: Mar 13, 2013
• Last Verified: Mar 1, 2013

• Keywords provided by Susan P. Perrine, Sponsor Investigator, Boston University: Thalassemia; Anemia; Fetal hemoglobin
• Additional relevant MeSH terms: Thalassemia; beta-Thalassemia

Study Results

No Results Posted as of Mar 13, 2013